Two young companies from the Swiss Federal Institute of Technology Zurich have swept the Venture Awards. Baxiva develops vaccines against antibiotic-resistant bacteria, such as those that cause urinary tract infections. RegCheck, meanwhile, offers an artificial intelligence platform for companies in regulated sectors to review documents and avoid errors before submitting them to authorities. For citizens, this means advances in health and safer medicines, as well as more efficient processes that can reduce costs.
Vaccines and machines that read papers 🧬
Baxiva targets pathogens that are becoming immune to current treatments, a growing threat in hospitals. Its vaccine trains the immune system to identify and destroy these bacteria before they cause serious infections. RegCheck, in parallel, trains its AI to detect inconsistencies in technical or regulatory documents. The system compares the text with current regulations and flags potential errors. This reduces review time and prevents incomplete packages from reaching control agencies, such as those for medical technology.
The robot that saves you from bureaucratic headaches 🤖
While Baxiva tackles increasingly tough bugs, RegCheck faces an equally fearsome enemy: paperwork. Because we all know that filling out forms for authorities can be more dangerous than a bacterium. At least the bacterium attacks your body; bureaucracy attacks your patience. Now, an artificial intelligence will take care of checking if you added an extra comma. The future is bright: fewer infections and, hopefully, fewer afternoons wasted filling out applications.